Clinical trials: Primary Immunoglobulin A Nephropathy

IgA Nephropathy

Study of CM313 in Subject With IgA Nephropathy

• Not yet recruiting
• Age: 18 to 75 years
• Phase 2

This study is divided into two parts (Part A and Part B). This study aims to evaluate the safety and efficacy of CM313 in subjects with primary Immunoglobulin A nephropathy(IgAN), while also observing its Pharmacokinetics(PK)…

Trial name

NCT06830395

Testing

CM313

Where

China

Volunteers

106 people

Sponsor

Keymed Biosciences Co.Ltd